PMC:7796052 / 15566-15690 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"398","span":{"begin":98,"end":109},"obj":"Gene"},{"id":"404","span":{"begin":50,"end":60},"obj":"Chemical"}],"attributes":[{"id":"A398","pred":"tao:has_database_id","subj":"398","obj":"Gene:624"},{"id":"A404","pred":"tao:has_database_id","subj":"404","obj":"MESH:D020849"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" a drug repurposing campaign. Results showed that raloxifene is a weak partial agonist toward the B2 receptor, with a 19% ef"}